Resmonics

What Resmonics does

Resmonics AG is a Swiss digital health company founded in October 2020 as a spin-off from ETH Zurich and the University of St. Gallen. The company develops acoustic artificial intelligence for respiratory health monitoring and infection prevention, anchored by ResGuard Med, a CE-certified Software as a Medical Device that analyzes cough sounds via smartphone microphones or IoT sensors to detect cough frequency, classify dry versus productive coughs, and predict respiratory infection waves up to two weeks in advance, with claimed accuracy exceeding 95% on smartphones. The underlying research program originated in 2016 with the Asthma Control Prediction multicenter trial.

The company operates a multi-channel distribution model: ResGuard Med is offered as an SDK for smart-device integration, a browser-based API, and a white-label smartphone application (myCough); the RAI Sensor System and Quorum product lines provide IoT-based ambient monitoring for hospitals and workplaces; and a Clinical Research Dashboard supports decentralized clinical trials. Revenue is generated through SDK licensing, white-label app distribution, hardware sales of sensor units, API access, and clinical trial services. Go-to-market is sales-led for enterprise healthcare accounts, complemented by OEM/embedded licensing and API-first deployment, with strategic distribution partners including Bayer Vital GmbH (browser-based cough checker on the Phytohustil platform in Germany, reaching 4M+ users) and CSS (Swiss health insurance).

Resmonics serves four primary customer segments — hospitals and healthcare providers, pharmaceutical and MedTech companies, health insurers, and enterprise employers — with deployment evidence in Switzerland, Germany, Finland, China, New Zealand, and Canada. Named enterprise customers include Kantonsspital Baden AG and Bayer Vital GmbH. The company has published 15 peer-reviewed scientific contributions, holds a granted patent on its cough-monitoring technology, and reports headcount of 1–10 employees with active hiring across AI, engineering, and product roles.

Name

Resmonics

Legal name

Resmonics AG

Website

https://resmonics.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Resmonics AG is a Swiss digital health startup that develops CE-certified acoustic AI technology (ResGuard Med) for respiratory symptom monitoring and hospital infection prevention, serving hospitals, pharmaceutical companies, and health insurers via SDK, API, and IoT sensor products.

Ownership category

akta.pro rank

Product category

Digital Health Respiratory Monitoring Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

akta.pro secondary industries

Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), EHR/EMR Integration & Interoperability Middleware (HL7/FHIR) (HLALAKAD)

Keywords

• Acoustic AI healthcare
• Respiratory symptom monitoring
• Infection prevention sensors
• Medical device software
• Digital cough biomarker

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. SDK Licensing: ResGuard Med offered as Software Development Kit for integration into smartphone apps or smart devices. Revenue from licensing fees to MedTech companies, pharmaceutical partners, and hardware manufacturers.
2. White-label App Licensing: Fully customizable white-label app for Android and iOS for nocturnal cough monitoring. Sold to healthcare providers, pharmaceutical companies, and health insurances.
3. RAI Sensor Hardware: Sale of IoT AI-enabled sensor devices for hospital and workplace deployment. Sensors provide continuous monitoring with visual color indicators for infection risk.
4. API Access / Browser-based Solutions: Browser-based cough assessment via API integration. Powers third-party platforms like Bayer's Phytohustil with per-use or subscription-based API access.
5. Clinical Trial Solutions: End-to-end solutions for decentralized clinical trials including patient-reported outcomes and multi-modal digital biomarker measurements.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Resmonics develops ambient acoustic artificial intelligence to detect and analyze respiratory symptoms such as cough as a digital biomarker for infection prevention and lung health management. Its core product, ResGuard Med, is a CE-certified software as a medical device delivered as an SDK for smart devices, an API for web browsers, and a white-label smartphone app (myCough), complemented by the RAI Sensor System and Quorum IoT devices for continuous indoor infection risk monitoring in hospitals and workplaces.

Product overview

Resmonics offers a portfolio of acoustic AI-powered healthcare products centered on respiratory health monitoring and infection prevention. The core technology is ResGuard Med, a CE-certified medical software available as SDK, browser API, and white-label smartphone app (myCough). This is complemented by the RAI Sensor System and Quorum IoT devices for hospital and workplace infection monitoring. The portfolio spans consumer-facing apps for at-home nocturnal cough monitoring, clinical research tools with dashboards, and enterprise IoT sensor systems for real-time infection wave detection in healthcare facilities. All products leverage proprietary acoustic AI to analyze cough as a digital biomarker.

Differentiator

Problem solved

Functional benefit

Brands

• ResGuard Med: CE-certified medical software as a device capable of detecting and analyzing respiratory symptoms such as cough. Available as SDK for smart devices, API for web browsers, and white-label smartphone app.
• myCough
• RAI Sensor System
• Quorum

Products and services

• ResGuard Med CE-certified software as a medical device that analyzes cough frequency, quality (dry vs. productive), severity, and intensity from audio recordings using acoustic AI, available as SDK, browser API, and white-label smartphone app for healthcare providers, pharmaceutical partners, and MedTech integrators.
• myCough White-label smartphone app for Android and iOS that monitors nocturnal cough to provide patients and physicians with objective, medically validated lung health parameters, including a traffic-light interpretation system for health deteriorations.
• RAI Sensor System Hospital-based IoT AI-enabled sensor system for early detection of respiratory infection risks, providing continuous non-invasive monitoring of cough activity and sound patterns with visual color indicators for elevated infection risk.
• Quorum IoT AI-enabled smart sensor platform for indoor spaces that passively analyzes data sources including cough sounds to determine respiratory infection risk and protect workforce health in real-time within workplace environments.
• ResGuard Med SDK Software Development Kit that enables third-party developers to integrate ResGuard Med's acoustic AI respiratory symptom monitoring into their own smartphone apps or smart devices, licensed to MedTech and pharmaceutical partners.
• Clinical Research Dashboard Web dashboard enabling clinical study teams to monitor progress and results of respiratory symptom measurements in real time, supporting decentralized clinical trials with PDF export and patient-reported outcomes.
• Browser-Based Acoustic AI Cough Checker Browser-based cough assessment tool powered by ResGuard Med, allowing users to record and analyze approximately five-second audio samples of their cough directly in the browser and distinguishing between dry and productive cough types, deployed via Bayer's Phytohustil platform in Germany.

Quantifiable outcome

• 75% of asthma attacks predicted up to 4 days in advance using nocturnal cough analysis
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hyfe: Hyfe builds acoustic AI for continuous cough monitoring and respiratory disease surveillance—the closest direct competitor to ResGuard Med, with overlapping technology (cough sound classification) and overlapping use cases in pharma clinical trials, public health, and consumer health.
• ResApp Health: ResApp Health (acquired by Pfizer in 2022) developed smartphone-based cough analysis AI for diagnosing respiratory diseases such as pneumonia, asthma, and COPD—directly comparable technology to ResGuard Med, with similar clinical-grade accuracy claims and pharma-backed distribution.
• SoundHealth (formerly Strados Labs): SoundHealth uses acoustic AI and wearable sensors to monitor respiratory biomarkers including cough and lung sounds for asthma, COPD, and IPF management—a direct competitor in respiratory sound AI targeting pharma clinical trials and patient monitoring.
• Sonavi Labs: Sonavi Labs develops AI-powered digital stethoscopes and acoustic analysis tools for respiratory and pulmonary disease detection—overlapping acoustic AI approach and similar clinical application to ResGuard Med and RAI Sensor System.
• Aural Analytics: Aural Analytics applies speech and acoustic biomarker AI for clinical assessment of respiratory and neurological conditions—comparable technology stack and pharma clinical trial go-to-market to Resmonics' SDK/API offering.

Broad incumbents

• Eko Health: Eko Health is a well-funded digital health company with FDA-cleared AI for cardiac and respiratory sound analysis via connected stethoscopes. Its broader platform and US regulatory footprint make it a larger incumbent competing for similar hospital and clinical use cases.
• Propeller Health (ResMed): Propeller Health, owned by ResMed, is an established digital respiratory health platform with sensor-enabled inhalers and analytics for asthma/COPD—competes for the same pharma and hospital budgets but is a much larger incumbent with FDA-cleared hardware.
• Vitalograph: Vitalograph manufactures respiratory diagnostic devices and clinical trial endpoints for spirometry and cough monitoring—a longer-established player in respiratory measurement with comparable clinical research customer base.

Emerging players

• NuvoAir: NuvoAir offers a respiratory care platform combining remote spirometry, symptom tracking, and clinician dashboards for COPD and asthma—adjacent to Resmonics' respiratory monitoring focus with overlapping target customer (specialty pharma, payers, hospitals) but a different sensor modality.

Others

• Sema4 (now part of GeneDx): Sema4 is a clinical intelligence and digital health platform with data-driven respiratory and infection disease analytics—an adjacent, enabling player in the broader data-driven respiratory health space rather than a direct acoustic AI competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/resmonics
• LinkedInlinkedin.com/company/resmonics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resmonics